Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The launch of the MDUK Oxford Neuromuscular Centre marks an exciting new stage in the partnership between Muscular Dystrophy UK and the University of Oxford, with the goal of delivering new experimental medicines and developing enhanced clinical trial capacity in adult and paediatric neuromuscular diseases.

Oxford boasts a long and rich history of neuromuscular research, going as far back as 1672, when Thomas Willis, a Christ Church graduate, first described Myasthenia Gravis. In more recent years, fundamental advances in the field have been made by Professors John Newsom-Davis and Angela Vincent, who have performed the first studies on plasma exchange in myasthenia patients in 1972 and discovered antibodies to a new muscle-specific tyrosine kinase receptor MuSK in myasthenia in 2001. In the 1980s, Professor Kay Davies – the Centre’s co-founder and key driver – developed the first prenatal diagnosis for Duchenne muscular dystrophy, described the localisation of the DMD gene and discovered utrophin, a dystrophin-like protein whose increased expression may be able to compensate for the lack of the dystrophin protein in persons with DMD.

Fittingly, over the past few decades, Oxford has also maintained a strong connection with Muscular Dystrophy UK. Since 1988, MDUK has funded 75 projects and provided Oxford researchers with £8,500,000 in financial support. The charity’s flagship fundraising event, the Town and Gown run, was founded in 1982 in Oxford.

The potential of the two institutions is now combined in the shape of the MDUK Oxford Neuromuscular Centre. Currently, unprecedented number of neuromuscular therapies are coming to trial worldwide. Complex therapies, such a gene therapies, require appropriate infrastructure, as well as expertise to design, train and lead trials. The launch of the Centre will enhance trial capacity, and, consequently, accelerate pre-clinical discovery and translation, catalyse new experimental therapies and establish neuromuscular-focused training.

The Centre was officially inaugurated on October 8th, 2019, with speeches from its Director, Professor Matthew Wood, Project Manager Dr Nicole Le Grand and from MDUK’s Director of Research and Innovation, Dr Kate Adcock. The opening was followed by a keynote lecture from Laurent Servais, the newly appointed Professor of Paediatric Neuromuscular Disease, who gave an overview of his ground-breaking work on Duchenne muscular dystrophy and spinal muscular atrophy. The evening concluded with a reception and an exhibition of current neuromuscular research from key investigators across the Centre.

Similar stories

Innovation award for Paediatrics researcher to develop new treatments for childhood cancer

Awards & Appointments Haematology

Associate Professor Andi Roy leads one of the five research teams across the UK that have been awarded the 2021 Cancer Research UK-Children with Cancer UK Innovation Award. The awards, which provide a total of £4.3 million in scientific funding, will allow leading researchers in the field to delve into the biology of children’s and young people’s cancers, with the hope of finding new ways to prevent and treat these complex cancers.

Professor Matthew Snape named NIHR Senior Investigator

Awards & Appointments Vaccinology

Four academics supported by the NIHR Oxford Biomedical Research Centre have been awarded a prestigious national award, among them Matthew Snape from the Oxford Vaccine Group.

University spinout PepGen awarded major financing to target Duchenne muscular dystrophy

Awards & Appointments Neuromuscular Diseases

PepGen, a therapeutics company targeting severe neuromuscular diseases, including Duchenne muscular dystrophy (DMD), has closed a $45 million Series A funding round led by RA Capital Management with participation from Oxford Sciences Innovation (OSI), the company’s original seed investor.

Enriching Engagement (Round 2) awardees announced

Awards & Appointments Neuromuscular Diseases Public Engagement

The awardees for the second round of the University of Oxford’s Enriching Engagement funding scheme have now been announced, including a project from Paediatrics.

Typhoid vaccine project wins Vice-Chancellor award

Awards & Appointments Vaccinology

Congratulations to Professor Andrew Pollard who is the Winner of the Policy Engagement category in the Vice-Chancellor Innovation Awards 2020 for his work on Global policy on typhoid vaccines through research at Oxford!

Coronavirus: is it safe for children to return to school?

COVID-19 Children's Health General Parents & Carers

Stéphane Paulus and Else Bijker explore the topic in their article for The Conversation.